Kala Pharmaceuticals (NASDAQ:KALA) received a $35.00 price objective from investment analysts at HC Wainwright in a report released on Thursday. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 188.30% from the company’s previous close.

A number of other research firms have also commented on KALA. Zacks Investment Research lowered Kala Pharmaceuticals from a “buy” rating to a “sell” rating in a research note on Wednesday. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Kala Pharmaceuticals in a research note on Wednesday, June 20th. ValuEngine upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, BidaskClub upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $30.00.

Shares of NASDAQ KALA opened at $12.14 on Thursday. The company has a market cap of $309.86 million and a PE ratio of -2.08. The company has a debt-to-equity ratio of 0.27, a quick ratio of 9.79 and a current ratio of 9.79. Kala Pharmaceuticals has a 1-year low of $11.39 and a 1-year high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its earnings results on Thursday, August 9th. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.10). equities research analysts predict that Kala Pharmaceuticals will post -1.95 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. American International Group Inc. increased its stake in Kala Pharmaceuticals by 86.6% during the 1st quarter. American International Group Inc. now owns 9,119 shares of the company’s stock worth $144,000 after acquiring an additional 4,232 shares during the period. Teachers Advisors LLC increased its stake in Kala Pharmaceuticals by 44.6% during the 4th quarter. Teachers Advisors LLC now owns 21,006 shares of the company’s stock worth $388,000 after acquiring an additional 6,478 shares during the period. New York State Common Retirement Fund increased its stake in Kala Pharmaceuticals by 94.7% during the 1st quarter. New York State Common Retirement Fund now owns 14,600 shares of the company’s stock worth $231,000 after acquiring an additional 7,100 shares during the period. MetLife Investment Advisors LLC bought a new position in Kala Pharmaceuticals during the 1st quarter worth $119,000. Finally, Bank of New York Mellon Corp increased its stake in Kala Pharmaceuticals by 23.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 41,327 shares of the company’s stock worth $568,000 after acquiring an additional 7,784 shares during the period. Hedge funds and other institutional investors own 77.33% of the company’s stock.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: Fundamental Analysis

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.